QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:LTRN

Lantern Pharma (LTRN) Competitors

$5.28
+0.12 (+2.33%)
(As of 05:21 PM ET)
Compare
Today's Range
$5.26
▼
$5.49
50-Day Range
$4.56
▼
$5.60
52-Week Range
$4.05
▼
$6.59
Volume
32,004 shs
Average Volume
31,447 shs
Market Capitalization
$57.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

LTRN vs. IOBT, GLTO, LFVN, ABEO, CNTB, ADAG, PIRS, ALZN, GANX, and MYNZ

Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include IO Biotech (IOBT), Galecto (GLTO), LifeVantage (LFVN), Abeona Therapeutics (ABEO), Connect Biopharma (CNTB), Adagene (ADAG), Pieris Pharmaceuticals (PIRS), Alzamend Neuro (ALZN), Gain Therapeutics (GANX), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical preparations" industry.

Lantern Pharma vs.

Lantern Pharma (NASDAQ:LTRN) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.

Lantern Pharma has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of -0.69, suggesting that its stock price is 169% less volatile than the S&P 500.

Lantern Pharma received 4 more outperform votes than IO Biotech when rated by MarketBeat users.

CompanyUnderperformOutperform
Lantern PharmaOutperform Votes
12
80.00%
Underperform Votes
3
20.00%
IO BiotechOutperform Votes
8
80.00%
Underperform Votes
2
20.00%

In the previous week, IO Biotech had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 2 mentions for IO Biotech and 0 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.00 beat IO Biotech's score of -0.83 indicating that Lantern Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Lantern Pharma Neutral
IO Biotech Negative

21.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 53.2% of IO Biotech shares are held by institutional investors. 6.9% of Lantern Pharma shares are held by insiders. Comparatively, 3.5% of IO Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lantern Pharma's return on equity of -24.53% beat IO Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantern Pharma N/A -24.53% -23.10%
IO Biotech N/A -48.61% -45.18%

Lantern Pharma currently has a consensus target price of $11.00, indicating a potential upside of 108.33%. IO Biotech has a consensus target price of $11.00, indicating a potential upside of 436.59%. Given IO Biotech's stronger consensus rating and higher possible upside, analysts clearly believe IO Biotech is more favorable than Lantern Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantern Pharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
IO Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Lantern Pharma is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantern PharmaN/AN/A-$14.26 million-$1.29-4.09
IO BiotechN/AN/A-$71.46 million-$2.48-0.83

Summary

Lantern Pharma beats IO Biotech on 8 of the 14 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LTRN vs. The Competition

Export to Excel
MetricLantern PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$57.34M$5.92B$4.53B$6.22B
Dividend YieldN/A2.60%5.94%6.49%
P/E Ratio-4.094.8999.5812.31
Price / SalesN/A333.793,482.0288.70
Price / CashN/A18.9691.71104.84
Price / Book1.024.854.725.29
Net Income-$14.26M$195.94M$117.43M$192.85M
7 Day Performance1.34%6.56%6.30%4.98%
1 Month Performance5.39%4.98%4.52%5.96%
1 Year Performance-7.37%16.25%12.17%1.62%

Lantern Pharma Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IOBT
IO Biotech
1.9058 of 5 stars		$2.07
+2.0%		$11.00
+431.4%		-58.2%$59.66MN/A-0.8319
GLTO
Galecto
2.099 of 5 stars		$2.30
+2.7%		$11.67
+407.2%		+4.4%$59.04MN/A-1.0128
LFVN
LifeVantage
1.2577 of 5 stars		$4.60
+0.9%		N/A+6.4%$58.88M$206.36M-76.67263Gap Up
High Trading Volume
ABEO
Abeona Therapeutics
2.4546 of 5 stars		$3.08
-1.9%		$22.00
+614.3%		+1.5%$57.84M$1.41M0.00N/A
CNTB
Connect Biopharma
2.6406 of 5 stars		$1.11
-4.3%		$7.00
+530.7%		+43.0%$61.09MN/A0.0062Positive News
ADAG
Adagene
1.8858 of 5 stars		$1.32
-6.4%		$5.00
+278.8%		-52.9%$57.09M$9.29M0.00198High Trading Volume
PIRS
Pieris Pharmaceuticals
1.936 of 5 stars		$0.76
+1.3%		N/A-49.4%$61.93M$25.90M-1.35124Gap Up
ALZN
Alzamend Neuro
2.1235 of 5 stars		$0.64
flat		$1.50
+134.3%		-26.9%$62.06MN/A-3.773
GANX
Gain Therapeutics
2.2357 of 5 stars		$4.59
flat		$8.15
+77.6%		+43.8%$56.60M$140,000.00-2.8225Positive News
MYNZ
Mainz Biomed
1.8049 of 5 stars		$5.19
-0.8%		$11.00
+111.9%		-53.9%$62.33M$530,000.000.00N/AGap Up

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:LTRN) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -